Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance:
Advanced therapies Why promoter design is no longer just an expression checkbox, it’s the key…
1 October 2023
Updates – October 2023
Annogen is excited to share our latest break through in cellular engineering. We’ve successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline expression and high inducibility with added stimulus. Our HEK293-INDX1™ clone is displayed in the image below.
We believe that having production clones with the ability to express a gene conditionally, allows for robust expansion of stable clones and subsequent high expression at scale. We are open to collaborations and would be excited to hear the potential you see in HEK293-INDX1™ or, more generally, in similar approaches applied to other production systems such as SF9, CHO, etc.
We use our SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein production.
Annogen scaled its proprietary gene-insertion and expression mapping strategy AIM™ to unprecedented numbers. It can identify gene insertions and asses their expression levels for >100,000 integrations in parallel. This is also valuable in support of Cell Therapy, particularly for development of #allogeneic platforms as well as improving #celllinegeneration for protein and virus production (CDMOs).
If you are interested in learning more about Annogen, our work, or potential collaborations, please reach out to info@annogen.bio!
